Cargando…

Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)

BACKGROUND: Few data have been published on the clinical and histopathological characteristics of advanced non-small–cell lung cancer (NSCLC) patients with high PD-L1 expression versus intermediate or none and the prognostic value of PD-L1 expression for patients treated with chemotherapy is unknown...

Descripción completa

Detalles Bibliográficos
Autores principales:	Auliac, Jean-Bernard, Guisier, Florian, Bizieux, Acya, Assouline, Pascal, Bernardini, Marie, Lamy, Régine, Justeau, Grégoire, François, Geraldine, Damotte, Diane, Chouaïd, Christos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779294/ https://www.ncbi.nlm.nih.gov/pubmed/33408480 http://dx.doi.org/10.2147/OTT.S288825

Ejemplares similares

PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 “EPNEC” study
por: Arpin, Dominique, et al.
Publicado: (2020)

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
por: Auliac, Jean-Bernard, et al.
Publicado: (2020)

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
por: Bylicki, Olivier, et al.
Publicado: (2020)

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)
por: Christos, Chouaid, et al.
Publicado: (2012)

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14
por: Auliac, Jean-Bernard, et al.
Publicado: (2019)

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)
por: Vergnenègre, Alain, et al.
Publicado: (2019)

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)
por: Vergnenegre, Alain, et al.
Publicado: (2019)

Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)
por: Corre, Romain, et al.
Publicado: (2018)

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
por: Raynaud, C., et al.
Publicado: (2015)

Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC
por: Lesueur, Paul, et al.
Publicado: (2018)

Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)
por: Martel-Lafay, Isabelle, et al.
Publicado: (2021)

Detection of EGFR Mutations in the Plasma of Patients with Lung Adenocarcinoma for Real-Time Monitoring of Therapeutic Response to Tyrosine Kinase Inhibitors?
por: Marcq, Marie, et al.
Publicado: (2014)

Cancer risk in adherent users of polyurethane foam-containing CPAP devices for sleep apnoea
por: Justeau, Grégoire, et al.
Publicado: (2022)

First-line management of advanced non-small-cell lung cancer: can we do better?
por: Chouaïd, Christos, et al.
Publicado: (2023)

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
por: Gendarme, Sébastien, et al.
Publicado: (2022)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
por: Borget, Isabelle, et al.
Publicado: (2014)

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
por: Descourt, Renaud, et al.
Publicado: (2022)

Effect on eNOS/NO Pathway in MIRI rats with preconditioning of GFPC from Dang Gui Si Ni decoction
por: Qian, Guo-qiang, et al.
Publicado: (2014)

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis
por: Monnet, Isabelle, et al.
Publicado: (2021)

CERN Bulletin Issue No. 06-07/2015
Publicado: (2015)

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)
por: LeCaer, H, et al.
Publicado: (2011)

Trial watch: Toll-like receptor ligands in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2023)

Influence of Marital Status and Employment Status on Long-Term Adherence with Continuous Positive Airway Pressure in Sleep Apnea Patients
por: Gagnadoux, Frédéric, et al.
Publicado: (2011)

EPCT-06. PRECISION ONCOLOGY IN THE PEDIATRIC TARGETED THERAPY 2.0 PROGRAM
por: Ecker, Jonas, et al.
Publicado: (2021)

Independent Association Between Obstructive Sleep Apnea Severity and Glycated Hemoglobin in Adults Without Diabetes
por: Priou, Pascaline, et al.
Publicado: (2012)

CMS Virtual Visit from Poland - 20.06.2015
por: Krzysztof, Juszczak, et al.
Publicado: (2015)

CMS Virtual Visit from Poland - 20.06.2015
por: Lapka, Marzena
Publicado: (2015)

CMS Virtual Visit from Poland - 18.06.2015
por: Lapka, Marzena
Publicado: (2015)

GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes
por: von Richter, Oliver, et al.
Publicado: (2016)

EPCT-06. A PHASE I STUDY OF MULTI-TARGETED THERAPY IN NEWLY DIAGNOSED OR PROGRESSIVE DIFFUSE INTRINSIC PONTINE GLIOMA
por: Baig, Muhammad, et al.
Publicado: (2020)

CMS Virtual Visit from Russia (Dubna) - 23.06.2015
por: Beni, Noemi
Publicado: (2015)

Digital broadcasting set to transform communication landscape by 2015: RRC-06
Publicado: (2006)

Immunopotentiation of Trivalent Influenza Vaccine When Given with VAX102, a Recombinant Influenza M2e Vaccine Fused to the TLR5 Ligand Flagellin
por: Talbot, H. Keipp, et al.
Publicado: (2010)

Assessing the feasibility of confocal laser endomicroscopy in solitary pulmonary nodules for different part of the lungs, using either 0.6 or 1.4 mm probes
por: Hassan, Tidi, et al.
Publicado: (2017)

Cumulative Association of Obstructive Sleep Apnea Severity and Short Sleep Duration with the Risk for Hypertension
por: Priou, Pascaline, et al.
Publicado: (2014)

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2019)

TIPS-06 ADVANCING BEYOND THE HIPPOCAMPUS TO PRESERVE COGNITION FOR PATIENTS WITH BRAIN METASTASES: DOSIMETRIC RESULTS FROM A PHASE 2 TRIAL OF MEMORY-AVOIDANCE WHOLE BRAIN RADIOTHERAPY
por: Perlow, Haley K, et al.
Publicado: (2023)

Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer
por: Elliott, Daisy, et al.
Publicado: (2018)

Exploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed‐methods approach
por: Tan, Wei Shen, et al.
Publicado: (2020)

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer
por: Mostafid, A. Hugh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_im03skqjca3dfhkglq6r69vnk5